A peripheral blood ELISpot approach quantifying CEA-specific T-cell responses was linked to outcomes in colorectal cancer treated with anti-PD-1 therapy. The study reports that CEA-specific immune activity in blood predicts both treatment response and progression-free survival. The key clinical implication is potential stratification: by identifying patients with stronger CEA-directed T-cell reactivity, clinicians may better estimate benefit likelihood from checkpoint blockade in colorectal cancer. The work also underscores the shift toward functional immune readouts rather than purely expression-based biomarkers. For biotech, the result provides a rationale for prospective validation of CEA ELISpot as an easy-to-deploy stratification tool, which could support trial enrichment strategies and potentially improve precision in immunotherapy selection.
Get the Daily Brief